Further Reading
The publications below cover a range of topics related to the use of PET imaging in
drug development and in the characterization of central nervous system disorders.
drug development and in the characterization of central nervous system disorders.
Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept
with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003 Sep;59(5-6):
357-66.
Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, Buchsbaum MS, Mantil JC. Measuring
dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release
during a spatial attention task. Neuroimage. 2006 May 15;31(1):139-52.
Dickerson BC, Sperling RA. Neuroimaging Biomarkers for Clinical Trials of Disease-Modifying
Therapies in Alzheimer's Disease. Neurorx. 2005 Apr; 2(2): 348–360.
Gee AD. Neuropharmacology and drug development. Br Med Bull. 2003;65:169-77.
Goerendt IK et al. Distributed neural actions of anti-parkinsonian therapies as revealed by PET. J
Neural Transm. 2005 Jul 29.
Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in
neuropsychopharmacological drug development. Curr Pharm Des 2001 Dec;7(18):1907-29.
Kapur S. Neuroimaging and drug development: an algorithm for decision making. J Clin
Pharmacology 2001 Jul;Suppl:64S-71S.
Lukic AS, Wernick MN, Strother SC. An evaluation of methods for detecting brain activations from
functional neuroimages. Artif Intell Med. 2002 May;25(1):69-88.
Mendelson WB et al. The treatment of chronic insomnia: drug indications, chronic use and abuse
liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med
Review 2004 Feb;8(1):7-17
Mendelson WB. Neurotransmitters and sleep. J Clin Psychiatry. 2001;62 Suppl 10:5-8.
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E,
Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S,
de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment,
Alzheimer's disease, and other dementias. J Nucl Med. 2008 Mar;49(3):390-8.
Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ.
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008
May;29(5):676-92.
Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ. (18)F-FDG PET
database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive
impairment and Alzheimer's disease. J Nucl Med. 2007 Jul;48(7):1129-34.
Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta
PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ. Hypometabolism and Altered Cerebrospinal
Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints. Biol
Psychiatry. 2007 Aug 24; [Epub ahead of print]
Mosconi L, Tsui WH, Rusinek H, De Santi S, Li Y, Wang GJ, Pupi A, Fowler J, de Leon MJ.
Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild
Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1467-79.
Mosconi L et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image
analysis. Neurology. 2005, Jun 14:64(11):1860-7.
Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J. Evaluation of dopamine D-2 receptor
occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain
using 18F-fallypride. Neuropsychopharmacology. 2001 Oct;25(4):476-88.
Mukherjee J et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution,
test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3
receptors. Synapse. 2002 Dec 1;46(3):170-88.
Potkin SG et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. Int J
Neuropsychopharmacol. 2001 Sep;4(3):223-30.
Rusinek H, Endo Y, De Santi S, Frid D, Tsui WH, Segal S, Convit A, de Leon MJ. Atrophy rate in medial
temporal lobe during progression of Alzheimer disease. Neurology. 2004 Dec 28;63(12):2354-9.
Rusinek H, De Santi S, Frid D, Tsui WH, Tarshish CY, Convit A, de Leon MJ. Regional brain atrophy
rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology.
2003 Dec;229(3):691-6.
Strother SC, Anderson J, Hansen LK, Kjems U, Kustra R, Sidtis J, Frutiger S, Muley S, LaConte S,
Rottenberg D. The quantitative evaluation of functional neuroimaging experiments: the NPAIRS data
analysis framework. Neuroimage. 2002 Apr;15(4):747-71.
with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003 Sep;59(5-6):
357-66.
Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, Buchsbaum MS, Mantil JC. Measuring
dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release
during a spatial attention task. Neuroimage. 2006 May 15;31(1):139-52.
Dickerson BC, Sperling RA. Neuroimaging Biomarkers for Clinical Trials of Disease-Modifying
Therapies in Alzheimer's Disease. Neurorx. 2005 Apr; 2(2): 348–360.
Gee AD. Neuropharmacology and drug development. Br Med Bull. 2003;65:169-77.
Goerendt IK et al. Distributed neural actions of anti-parkinsonian therapies as revealed by PET. J
Neural Transm. 2005 Jul 29.
Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in
neuropsychopharmacological drug development. Curr Pharm Des 2001 Dec;7(18):1907-29.
Kapur S. Neuroimaging and drug development: an algorithm for decision making. J Clin
Pharmacology 2001 Jul;Suppl:64S-71S.
Lukic AS, Wernick MN, Strother SC. An evaluation of methods for detecting brain activations from
functional neuroimages. Artif Intell Med. 2002 May;25(1):69-88.
Mendelson WB et al. The treatment of chronic insomnia: drug indications, chronic use and abuse
liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med
Review 2004 Feb;8(1):7-17
Mendelson WB. Neurotransmitters and sleep. J Clin Psychiatry. 2001;62 Suppl 10:5-8.
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E,
Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S,
de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment,
Alzheimer's disease, and other dementias. J Nucl Med. 2008 Mar;49(3):390-8.
Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ.
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008
May;29(5):676-92.
Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ. (18)F-FDG PET
database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive
impairment and Alzheimer's disease. J Nucl Med. 2007 Jul;48(7):1129-34.
Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta
PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ. Hypometabolism and Altered Cerebrospinal
Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints. Biol
Psychiatry. 2007 Aug 24; [Epub ahead of print]
Mosconi L, Tsui WH, Rusinek H, De Santi S, Li Y, Wang GJ, Pupi A, Fowler J, de Leon MJ.
Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild
Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1467-79.
Mosconi L et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image
analysis. Neurology. 2005, Jun 14:64(11):1860-7.
Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J. Evaluation of dopamine D-2 receptor
occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain
using 18F-fallypride. Neuropsychopharmacology. 2001 Oct;25(4):476-88.
Mukherjee J et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution,
test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3
receptors. Synapse. 2002 Dec 1;46(3):170-88.
Potkin SG et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. Int J
Neuropsychopharmacol. 2001 Sep;4(3):223-30.
Rusinek H, Endo Y, De Santi S, Frid D, Tsui WH, Segal S, Convit A, de Leon MJ. Atrophy rate in medial
temporal lobe during progression of Alzheimer disease. Neurology. 2004 Dec 28;63(12):2354-9.
Rusinek H, De Santi S, Frid D, Tsui WH, Tarshish CY, Convit A, de Leon MJ. Regional brain atrophy
rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology.
2003 Dec;229(3):691-6.
Strother SC, Anderson J, Hansen LK, Kjems U, Kustra R, Sidtis J, Frutiger S, Muley S, LaConte S,
Rottenberg D. The quantitative evaluation of functional neuroimaging experiments: the NPAIRS data
analysis framework. Neuroimage. 2002 Apr;15(4):747-71.
Technology
Advanced BioImaging to Accelerate New Therapeutics
 | |  |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Copyright 2006-2008 Abiant, Inc. |